Immunologic, microbial, and epithelial interactions in atopic dermatitis

被引：139

作者：

Brunner, Patrick M. ^{[1
]}

Leung, Donald Y. M. ^{[2
]}

Guttman-Yassky, Emma ^{[3
,4
]}

机构：

[1] Rockefeller Univ, Lab Investigat Dermatol, 1230 York Ave, New York, NY 10021 USA

[2] Natl Jewish Hlth, Dept Pediat, Denver, CO USA

[3] Icahn Sch Med Mt Sinai, Dept Dermatol, 1 Gustav L Levy Pl, New York, NY 10029 USA

[4] Icahn Sch Med Mt Sinai, Lab Inflammatory Skin Dis, 1 Gustav L Levy Pl, New York, NY 10029 USA

来源：

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2018年 / 120卷 / 01期

基金：

美国国家卫生研究院;

关键词：

ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; THYMIC STROMAL LYMPHOPOIETIN; CUTANEOUS LYMPHOCYTE ANTIGEN; STAPHYLOCOCCUS-AUREUS; SKIN MICROBIOME; DOUBLE-BLIND; T-CELLS; PHOSPHODIESTERASE INHIBITOR; ANTIMICROBIAL PEPTIDES; TOPICAL TREATMENT;

D O I：

10.1016/j.anai.2017.09.055

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Objective: To provide an overview of studies contributing to the understanding of immunologic, microbial, and epithelial interactions in atopic dermatitis. Data Sources: PubMed literature review (2000-2017) and meeting abstracts from recent international dermatology conferences. Study Selections: Articles discussing primarily human disease. Results: Clinical studies showed that atopic dermatitis is a type 2 immune-centered disease with a systemic inflammatory component but with heterogeneous treatment responses. This suggests that other factors are likely involved in shaping the skin disease phenotype, including microbial dysbiosis and epidermal barrier dysfunction. Conclusion: Recent clinical investigation has significantly expanded our knowledge on disease pathogenesis in atopic dermatitis, and current and future clinical trials will most likely further help to elucidate this complex, heterogeneous skin disease. (C) 2017 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

引用

页码：34 / 41

页数：8

共 149 条

[1] IL-4 and IL-13 negatively regulate TNF-α- and IFN-γ-induced β-defensin expression through STAT-6, suppressor of cytokine signaling (SOCS)-1, and SOCS-3 [J].

Albanesi, Cristina ;

Fairchild, Heather R. ;

Madonna, Stefania ;

Scarponi, Claudia ;

De Pita, Ornella ;

Leung, Donald Y. M. ;

Howell, Michael D. .

JOURNAL OF IMMUNOLOGY, 2007, 179 (02) :984-992

[2]

Andreae Doerthe A, 2014, Pediatrics, V134 Suppl 3, pS160, DOI 10.1542/peds.2014-1817UU

[3] Psychosomatic analysis of atopic dermatitis using a psychological test [J].

Arima, M ;

Shimizu, Y ;

Sowa, J ;

Narita, T ;

Nishi, I ;

Iwata, N ;

Ozaki, N ;

Hashimoto, S ;

Matsunaga, K .

JOURNAL OF DERMATOLOGY, 2005, 32 (03) :160-168

[4] Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis [J].

Beck, Lisa A. ;

Thaci, Diamant ;

Hamilton, Jennifer D. ;

Graham, Neil M. ;

Bieber, Thomas ;

Rocklin, Ross ;

Ming, Jeffrey E. ;

Ren, Haobo ;

Kao, Richard ;

Simpson, Eric ;

Ardeleanu, Marius ;

Weinstein, Steven P. ;

Pirozzi, Gianluca ;

Guttman-Yassky, Emma ;

Suarez-Farinas, Mayte ;

Hager, Melissa D. ;

Stahl, Neil ;

Yancopoulos, George D. ;

Radin, Allen R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (02) :130-139

[5] Atopic Dermatitis [J].

Bieber, Thomas .

ANNALS OF DERMATOLOGY, 2010, 22 (02) :125-137

[6] Regulation of T cell immunity in atopic dermatitis by microbes: the Yin and Yang of cutaneous inflammation [J].

Biedermann, Tilo ;

Skabytska, Yuliya ;

Kaesler, Susanne ;

Volz, Thomas .

FRONTIERS IN IMMUNOLOGY, 2015, 6 :1-9

[7] Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial [J].

Bissonnette, R. ;

Papp, K. A. ;

Poulin, Y. ;

Gooderham, M. ;

Raman, M. ;

Mallbris, L. ;

Wang, C. ;

Purohit, V. ;

Mamolo, C. ;

Papacharalambous, J. ;

Ports, W. C. .

BRITISH JOURNAL OF DERMATOLOGY, 2016, 175 (05) :902-911

[8] Disease outcomes as a consequence of environmental influences on the development of the immune system [J].

Bjorksten, Bengt .

CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 9 (03) :185-189

[9] Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial [J].

Blauvelt, Andrew ;

de Bruin-Weller, Marjolein ;

Gooderham, Melinda ;

Cather, Jennifer C. ;

Weisman, Jamie ;

Pariser, David ;

Simpson, Eric L. ;

Papp, Kim A. ;

Hong, H. Chih-Ho ;

Rubel, Diana ;

Foley, Peter ;

Prens, Errol ;

Griffiths, Christopher E. M. ;

Etoh, Takafumi ;

Pinto, Pedro Herranz ;

Pujol, Ramon M. ;

Szepietowski, Jacek C. ;

Ettler, Karel ;

Kemeny, Lajos ;

Zhu, Xiaoping ;

Akinlade, Bolanle ;

Hultsch, Thomas ;

Mastey, Vera ;

Gadkari, Abhijit ;

Eckert, Laurent ;

Amin, Nikhil ;

Graham, Neil M. H. ;

Pirozzi, Gianluca ;

Stahl, Neil ;

Yancopoulos, George D. ;

Shumel, Brad .

LANCET, 2017, 389 (10086) :2287-2303

[10] IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes [J].

Boniface, K ;

Bernard, FX ;

Garcia, M ;

Gurney, AL ;

Lecron, JC ;

Morel, F .

JOURNAL OF IMMUNOLOGY, 2005, 174 (06) :3695-3702

← 1 2 3 4 5 6 7 8 9 10 →